JP2025503649A - うつ病の治療のための組成物及び方法 - Google Patents

うつ病の治療のための組成物及び方法 Download PDF

Info

Publication number
JP2025503649A
JP2025503649A JP2024541230A JP2024541230A JP2025503649A JP 2025503649 A JP2025503649 A JP 2025503649A JP 2024541230 A JP2024541230 A JP 2024541230A JP 2024541230 A JP2024541230 A JP 2024541230A JP 2025503649 A JP2025503649 A JP 2025503649A
Authority
JP
Japan
Prior art keywords
patient
treatment
esketamine
aticaplant
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503649A5 (https=
Inventor
シー. ドリヴェッツ,ウェイン
クリスティアン コルブ,ハートマス
サーハル サード,ジァド
Original Assignee
ヤンセン ファーマシューティカルズ,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ,インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ,インコーポレーテッド
Publication of JP2025503649A publication Critical patent/JP2025503649A/ja
Publication of JP2025503649A5 publication Critical patent/JP2025503649A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4737C-reactive protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/5412IL-6

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024541230A 2022-01-10 2023-01-09 うつ病の治療のための組成物及び方法 Pending JP2025503649A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263298060P 2022-01-10 2022-01-10
US63/298,060 2022-01-10
PCT/IB2023/050171 WO2023131921A1 (en) 2022-01-10 2023-01-09 Compositions and methods for the treatment of depression

Publications (2)

Publication Number Publication Date
JP2025503649A true JP2025503649A (ja) 2025-02-04
JP2025503649A5 JP2025503649A5 (https=) 2026-01-19

Family

ID=84981673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541230A Pending JP2025503649A (ja) 2022-01-10 2023-01-09 うつ病の治療のための組成物及び方法

Country Status (10)

Country Link
US (1) US20250064779A1 (https=)
EP (1) EP4463143A1 (https=)
JP (1) JP2025503649A (https=)
KR (1) KR20240132501A (https=)
CN (1) CN118843459A (https=)
AU (1) AU2023206048A1 (https=)
CA (1) CA3247733A1 (https=)
IL (1) IL314176A (https=)
MX (1) MX2024008619A (https=)
WO (1) WO2023131921A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
JP2022548233A (ja) * 2019-09-13 2022-11-17 ヤンセン ファーマシューティカルズ,インコーポレーテッド エスケタミンの鼻腔内投与

Also Published As

Publication number Publication date
EP4463143A1 (en) 2024-11-20
MX2024008619A (es) 2024-09-25
KR20240132501A (ko) 2024-09-03
CN118843459A (zh) 2024-10-25
IL314176A (en) 2024-09-01
US20250064779A1 (en) 2025-02-27
WO2023131921A1 (en) 2023-07-13
CA3247733A1 (en) 2023-07-13
AU2023206048A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
JP7807870B2 (ja) うつ病の治療のためのエスケタミン
JP2024516297A (ja) うつ病の治療のための組成物及び方法
US11998525B2 (en) Compositions and methods for the treatment of depression
JP6858131B2 (ja) 自閉症を治療するための組成物及び方法
JP2025508069A (ja) アチカプラントを含む組成物
EP4021432A2 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
JP2025503646A (ja) うつ病の治療のための組成物及び方法
JP2025502098A (ja) うつ病の治療のための組成物及び方法
JP2025503649A (ja) うつ病の治療のための組成物及び方法
JP2021530569A (ja) 自閉症を処置するための組成物および方法
US20250177350A1 (en) Compositions and methods for the treatment of depression
US20240238245A1 (en) Compositions and methods for the treatment of depression
JP7840873B2 (ja) うつ病の治療方法
US20240358693A1 (en) Methods of treating pain
EA050800B1 (ru) Композиции и способы лечения депрессии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260107